CUTANEOUS NEUROFIBROMA
Clinical trials for CUTANEOUS NEUROFIBROMA explained in plain language.
Never miss a new study
Get alerted when new CUTANEOUS NEUROFIBROMA trials appear
Sign up with your email to follow new studies for CUTANEOUS NEUROFIBROMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a cancer drug shrink NF1 skin tumors? early trial begins.
Disease control Recruiting nowThis early study tests if a drug called IMLYGIC, injected directly into skin tumors, is safe and feasible for adults with NF1 who have bothersome growths. Ten participants will receive up to four cycles of treatment. The goal is to see if the approach is tolerable and can be done…
Matched conditions: CUTANEOUS NEUROFIBROMA
Phase: PHASE1 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated May 17, 2026 14:00 UTC
-
New drug shows promise for NF1 skin tumors in early trial
Disease control Recruiting nowThis study tests a drug called mirdametinib in adults with NF1 who have at least 24 skin tumors (cutaneous neurofibromas). The goal is to find the safest dose and see if it can shrink the tumors. The trial involves 24 participants and is run at Johns Hopkins University.
Matched conditions: CUTANEOUS NEUROFIBROMA
Phase: PHASE1, PHASE2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated May 15, 2026 11:53 UTC